Helius Medical Technologies, Inc. Announces Partnership With Lovell Government Services to Expand Reach of PoNS Therapy
Helius Medical Technologies, Inc. Announces Partnership With Lovell Government Services to Expand Reach of PoNS Therapy
Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government Services ("Lovell"), an SBA-certified Service Disabled Veteran Owned Small Business ("SDVOSB"), to make the Company's Portable Neuromodulation Stimulator ("PoNS") device available to federal healthcare systems. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.
专注于为平衡和步态缺陷提供新型治疗性神经调节方法的神经科技公司Helius Medical Technologies, Inc.（纳斯达克股票代码：HSDT）（“Helius” 或 “公司”）今天宣布，它已与经SBA认证的残疾退伍军人所属服务小型企业（“SDVOSB”）合作生产该公司的便携式神经系统联邦医疗保健系统可以使用调制刺激器（“PonS”）设备。在美国，当与物理疗法结合使用时，PonS可用作短期步态缺陷治疗有轻度至中度多发性硬化症症状的成年人的步态缺陷。